Natera (NASDAQ:NTRA) Insider John Fesko Sells 1,438 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 1,438 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total transaction of $291,683.92. Following the completion of the sale, the insider owned 185,782 shares in the company, valued at $37,684,020.88. This represents a 0.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The shares were sold at an average price of $206.16, for a total transaction of $59,992.56.
• On Monday, April 27th, John Fesko sold 1,688 shares of Natera stock. The shares were sold at an average price of $204.10, for a total transaction of $344,520.80.
• On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The shares were sold at an average price of $204.13, for a total transaction of $144,319.91.

Natera Price Performance

Shares of Natera stock opened at $213.94 on Friday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The firm has a market capitalization of $30.64 billion, a P/E ratio of -131.25 and a beta of 1.57. The company’s 50 day moving average price is $201.85 and its two-hundred day moving average price is $215.63.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter last year, the business posted ($0.41) earnings per share. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Institutional investors have recently added to or reduced their stakes in the stock. Horizon Investments LLC grew its holdings in shares of Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC grew its holdings in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the last quarter. Savvy Advisors Inc. grew its holdings in shares of Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares during the last quarter. Finally, First Horizon Corp grew its holdings in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NTRA has been the subject of several analyst reports. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. raised their price target on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Morgan Stanley dropped their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. Finally, William Blair initiated coverage on shares of Natera in a research note on Tuesday, April 14th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $256.60.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.